在阿尔茨海默氏病的连续性中,基础前脑胆能系统的结构变化
Miriam Taza1, Taylor W Schmitz2, R Nathan Spreng3
1Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada.
Handbook of clinical neurology
|May 8, 2025
概括
基础前脑 (BF) 的结构变化及其预测在阿尔茨海默病 (AD) 中可以从早期阶段就检测到. 这些变化随着粉样蛋白/tau病理而恶化,可能表明BF是AD神经病理的起源.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 神经成像是一种神经成像.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 基础前脑 (BF) 在认知和记忆中起着至关重要的作用.
- 早期发现AD病理对于干预至关重要.
研究的目的:
- 审查阿尔茨海默病 (AD) 进展期间基础前脑 (BF) 结构变化的证据.
- 为了检查这些变化的可检测性,从前症状到临床AD阶段.
- 探索BF在AD神经病理和疾病传播中的作用.
主要方法:
- 对体内人类磁共振成像 (MRI) 研究的审查.
- 基底前脑结构变化的分析及其白质预测.
- 肌肉纤维变化与粉样蛋白和病理以及遗传风险的相关性.
主要成果:
- 基底前脑 (BF) 的结构变化在整个阿尔茨海默病 (AD) 连续过程中是显而易见的.
- 这些BF变化可以从AD的最早的症状前阶段检测到.
- 结构性变化被粉样蛋白和蛋白病理以及遗传风险因素加剧.
结论:
- 基础前脑 (BF) 在阿尔茨海默病 (AD) 中经历了显著的结构变化.
- 这些变化可以在早期检测到,并且随着疾病的进展和病理变化而恶化.
- BF被认为是AD神经病理学的潜在起源地,支持了跨突触传播假设.
相关概念视频
Alzheimer's Disease: Overview
323
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
323
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview
319
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
319
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Role of Neurotransmitters in Memory
311
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
311
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85


